Gossamer lays off 25% of employees, cuts all programs except PAH drug

Amber Tong

As Gossamer Bio goes all in on its lead drug for pulmonary arterial hypertension (PAH), it’s cutting off all other clinical and preclinical programs …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Gossamer lays off 25% of employees, cuts all programs except PAH drug

Amber Tong

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

China startup injects CRISPR therapy into the brain for the first time

Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study

Roivant brings rare disease program closer as Immunovant CEO retires

FDA approves Dupixent for hives, rejects new Eylea dosing schedule

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Gos­samer lays off 25% of em­ploy­ees, cuts all pro­grams ex­cept PAH drug

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Gossamer lays off 25% of employees, cuts all programs except PAH drug